S. Ehrenforth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
S. Ehrenforth has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
I Scharrer
5 shared publicationsC Ruppert
2 shared publicationsH G Koch
Department of Paediatrics University Hospital, Münster, Germany
2 shared publicationsR Junker
Department of Paediatrics University Hospital, Münster, Germany
2 shared publications- Ulrike Nowak-GötTl
Department of Pediatric Hematology/Oncology, University of Münster, Germany
2 shared publications W Kreuz
Department of Internal Medicine, University Hospital Frankfurt, Germany
2 shared publications
Latest Publications
- 15 November 2000
- Vol. 96 (10) , 3364-8
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.
Elevation of serum lipoprotein (a) (Lp[a]) is a known risk factor predisposing to cardiovascular and cerebrovascular disease. However, little is known about the role of increased Lp(a) in venous thromboembolism (VTE). This study evaluated the role of Lp(a) among a panel of established hereditary thrombogenic defects in patients with VTE. A total of 685 consecutive patients with at least one episode of VTE and 266 sex- and age-matched healthy controls were screened with regard to activated protein C resistance, protein C, protein S, and antithrombin deficiency, elevated serum levels of Lp(a), and the factor V G1691A, MTHFR C677T, and prothrombin G20210A mutations. Elevated Lp(a) levels above 30 mg/dL were found in 20% of all patients, as compared to 7% among healthy controls (P <.001, odds ratio [OR] 3.2, 95% confidence interval [CI], 1.9-5.3). The coexistence of FV G1691A and elevated Lp(a) was significantly more prevalent among patients with VTE than in the control group (7% versus 0.8%; P <.001, OR 9.8, 95% CI, 2.4-40.7). No other established prothrombotic risk factor was found to be significantly combined with increased Lp(a). These data suggest that Lp(a) concentrations greater than 30 mg/dL are a frequent and independent risk factor for VTE. Furthermore, elevated Lp(a) levels might contribute to the penetrance of thromboembolic disease in subjects being affected by other prothrombotic defects, such as FV G1691A mutation.
- 15 November 2000
- Vol. 96 (10) , 3364-8
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.
Elevation of serum lipoprotein (a) (Lp[a]) is a known risk factor predisposing to cardiovascular and cerebrovascular disease. However, little is known about the role of increased Lp(a) in venous thromboembolism (VTE). This study evaluated the role of Lp(a) among a panel of established hereditary thrombogenic defects in patients with VTE. A total of 685 consecutive patients with at least one episode of VTE and 266 sex- and age-matched healthy controls were screened with regard to activated protein C resistance, protein C, protein S, and antithrombin deficiency, elevated serum levels of Lp(a), and the factor V G1691A, MTHFR C677T, and prothrombin G20210A mutations. Elevated Lp(a) levels above 30 mg/dL were found in 20% of all patients, as compared to 7% among healthy controls (P <.001, odds ratio [OR] 3.2, 95% confidence interval [CI], 1.9-5.3). The coexistence of FV G1691A and elevated Lp(a) was significantly more prevalent among patients with VTE than in the control group (7% versus 0.8%; P <.001, OR 9.8, 95% CI, 2.4-40.7). No other established prothrombotic risk factor was found to be significantly combined with increased Lp(a). These data suggest that Lp(a) concentrations greater than 30 mg/dL are a frequent and independent risk factor for VTE. Furthermore, elevated Lp(a) levels might contribute to the penetrance of thromboembolic disease in subjects being affected by other prothrombotic defects, such as FV G1691A mutation.
- 9 December 1999
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 158 (S3) , S97-S104
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood
To evaluate the role of multiple established and potential causes of childhood thrombophilia, 285 children with a history of thrombosis aged neonate to 18 years (first thrombotic onset) were investigated and compared with 185 healthy peers. APC- resistance (FV:Q506), protein C, protein S, antithrombin, heparin cofactor II (HCII), histidine-rich glycoprotein (HRGP), and prothrombin (F.II), factor XII (F.XII), plasminogen, homocysteine and lipoprotein (a) (Lp(a)) were investigated. In 59% of patients investigated one thrombotic defect was diagnosed, 19.6% showed two thrombotic risk factors, while in 21.4% of children investigated no risk factor could be identified. Single defects comprised established causes of inherited thrombophilia: FV:Q506 (homozygous n = 10, heterozygous n = 69), protein C (homozygous n = 1; heterozygous n = 31), heterozygous type I deficiency states of protein S (n = 7), antithrombin (n = 7) and homocystinuria (n = 6); potentially inherited clotting abnormalities which may be associated with thrombophilia: F.XII (n = 3), plasminogen (n = 2), HCII (n = 1), increased HRGP (n = 4); new candidate risk factors for thrombophilia: elevated plasma levels of Lp(a) (n = 26), F.II (n = 1). Heterozygous FV:Q506 was found in combination with heterozygous type I deficiency states of protein C (n = 2), protein S (n = 13), antithrombin (n = 8) and HCII (n = 1), increased Lp(a) (n = 13), and once each with elevated levels of F.II, moderate hyperhomocysteinemia, fibrinogen concentrations >700 mg/dl and increased HRGP. In addition to the association with FV:Q506, heterozygous protein C type I deficiency was combined with deficiencies of protein S (n = 2), antithrombin (n = 1), and increased Lp(a) (n = 3). One patient showed protein C deficiency along with familially increased von Willebrand factor >250%. Besides coexistence with FV:Q506 and protein C deficiency, protein S deficiency was combined with decreased F.XII and increased Lp(a) in one subject each. Furthermore, we found combinations of antithrombin deficiency/elevated Lp(a), hyperhomocysteinemia/Lp(a), deficiency of HCII/plasminogen, and plasminogen deficiency along with increased Lp(a) each in one. Increased prothrombin levels were associated with fibrinogen concentrations >700 mg/dl and with HCII deficiency in one child each. Carrier frequencies of single and combined defects were significantly higher in patients compared with the controls. Conclusion In conclusion, data of this multicentre evaluation indicate that paediatric thromboembolism should be viewed as a multifactorial disorder.
- 9 December 1999
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 158 (S3) , S97-S104
Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood
To evaluate the role of multiple established and potential causes of childhood thrombophilia, 285 children with a history of thrombosis aged neonate to 18 years (first thrombotic onset) were investigated and compared with 185 healthy peers. APC- resistance (FV:Q506), protein C, protein S, antithrombin, heparin cofactor II (HCII), histidine-rich glycoprotein (HRGP), and prothrombin (F.II), factor XII (F.XII), plasminogen, homocysteine and lipoprotein (a) (Lp(a)) were investigated. In 59% of patients investigated one thrombotic defect was diagnosed, 19.6% showed two thrombotic risk factors, while in 21.4% of children investigated no risk factor could be identified. Single defects comprised established causes of inherited thrombophilia: FV:Q506 (homozygous n = 10, heterozygous n = 69), protein C (homozygous n = 1; heterozygous n = 31), heterozygous type I deficiency states of protein S (n = 7), antithrombin (n = 7) and homocystinuria (n = 6); potentially inherited clotting abnormalities which may be associated with thrombophilia: F.XII (n = 3), plasminogen (n = 2), HCII (n = 1), increased HRGP (n = 4); new candidate risk factors for thrombophilia: elevated plasma levels of Lp(a) (n = 26), F.II (n = 1). Heterozygous FV:Q506 was found in combination with heterozygous type I deficiency states of protein C (n = 2), protein S (n = 13), antithrombin (n = 8) and HCII (n = 1), increased Lp(a) (n = 13), and once each with elevated levels of F.II, moderate hyperhomocysteinemia, fibrinogen concentrations >700 mg/dl and increased HRGP. In addition to the association with FV:Q506, heterozygous protein C type I deficiency was combined with deficiencies of protein S (n = 2), antithrombin (n = 1), and increased Lp(a) (n = 3). One patient showed protein C deficiency along with familially increased von Willebrand factor >250%. Besides coexistence with FV:Q506 and protein C deficiency, protein S deficiency was combined with decreased F.XII and increased Lp(a) in one subject each. Furthermore, we found combinations of antithrombin deficiency/elevated Lp(a), hyperhomocysteinemia/Lp(a), deficiency of HCII/plasminogen, and plasminogen deficiency along with increased Lp(a) each in one. Increased prothrombin levels were associated with fibrinogen concentrations >700 mg/dl and with HCII deficiency in one child each. Carrier frequencies of single and combined defects were significantly higher in patients compared with the controls. Conclusion In conclusion, data of this multicentre evaluation indicate that paediatric thromboembolism should be viewed as a multifactorial disorder.
- 1 June 1999
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 124 (25/26) , 783-787
APC-Resistenz und venöse Thrombophilie: Molekulargenetische Prävalenzstudie in der deutschen Bevölkerung
Grundproblematik und Fragestellung: Zu den bedeutendsten hereditären Gerinnungsdefekten, die mit einem gesteigerten venösen Thromboserisiko einhergehen, zählt die durch die Faktor-V-R506Q-Mutation (FV-Leiden-Mutation) bedingte Resistenz gegenüber aktiviertem Protein C (APC). Da bisher für die deutsche Bevölkerung kaum Daten zur genanalytisch validierten APC-Resistenz zur Verfügung stehen, bestand das Ziel der vorliegenden Untersuchung darin, in einer großen Untersuchungsgruppe deutscher Patienten mit juvenilen venösen Thromboembolien (VTE) und einer Kontrollgruppe gesunder Personen die Prävalenz der FV-Leiden-Mutation zu ermitteln. Patienten und Methodik: Insgesamt wurden konsekutiv 1200 Patienten (689 Frauen, 511 Männer) aus verschiedenen Regionen Deutschlands untersucht, die im Alter von ≤ 45 Lebensjahren an einer durch bildgebende Verfahren gesicherten primären tiefen Venenthrombose (TVT) und (oder) Lungenembolie (LE) erkrankt waren. Die Kontrollgruppe bestand aus 740 gesunden Probanden (332 Frauen, 408 Männer; medianes Alter 33 Jahre), bei denen sich in der Eigen- und Familienanamnese keine Hinweise für thromboembolische Ereignisse fanden. Die Analyse des FV-1691-Genotypes erfolgte mittels Mnll-Restriktionsanalyse von mit der Polymerase-Ketten-Reaktion amplifizierten genomischen FV-DNA-Fragmenten. Ergebnisse: In der Kontrollgruppe ergab sich eine Prävalenz von 7,5 % für die heterozygote FV:Q506-Mutante (25 Frauen, 30 Männer). Bei den untersuchten Patienten lag die FV R506Q-Mutation bei 27,2 % vor (23,1 % heterozygot [165 Frauen, 112 Männer]; 4,1 % homozygot [33 Frauen, 16 Männer]) und war somit signifikant häufiger als bei den gesunden Kontrollpersonen (P < 0,0001). Bei 81,3 % der FV:Q506-Patienten fand sich zum Zeitpunkt der Erstmanifestation eine TVT im Bein-Beckenvenenbereich, bei 14,4 % eine Thrombose in atypischer Lokalisation und bei 4,3 % eine isolierte Lungenembolie. Bei 36,5 % aller FV:Q506-Patienten (44 Frauen, 75 Männer) bzw. 53,1 % der homozygoten und 33,5 % der heterozygoten Mutationsträger trat das Erstereignis spontan auf. Folgerung: Die durch die FV-Leiden-Mutation bedingte APC-Resistenz ist die häufigste bekannte Ursache für venöse Thrombosen und scheint eine der häufigsten Erberkrankungen überhaupt zu sein, die sich auch in der deutschen Bevölkerung in einem hohen Prozentsatz nachweisen läßt. Die funktionelle und (oder) genotypische Untersuchung auf das Vorliegen einer APC-Resistenz sollte somit im Thrombophiliescreening stets berücksichtigt werden. Background and objective: Resistance against activated protein C (APC), caused by factor V R506Q mutation (factor V Leiden mutation), is among the most important hereditary clotting defects that are associated with an increased risk of venous thrombosis. As there are hardly any data for Germany regarding APC resistance that have been validated by genetic analysis, this study was undertaken to determine the prevalence of factor V Leiden (fVL) mutations in a sizeable group of patients in Germany with venous thromboembolism (VTE) and a control group of healthy persons. Patients and methods: 1200 consecutive patients (689 females, 511 males) from various regions of Germany were examined who, at an age between 0.1 and 45 years, had developed primary deep vein thrombosis (DVT) and/or pulmonary embolism (PE), as confirmed by imaging tests. The control group consisted of 740 healthy persons (332 females and 408 males; median age 33 years) for whom there was no evidence in their personal of family history of TE. Analysis of the fV-1691 genotype was by Mnll-restriction analysis of genomic fV DNA fragments, amplified by polymerase chain reaction. Results: The prevalence in the control group was 7.5 % the for heterozygotic fV: Q506 mutant (25 females, 30 males). For the patients the prevalence of the fV R506Q mutation was 27.2 % (32.1 % heterozygotes [165 females, 112 males]; 4.1 % homozygotes [33 females, 16 males], i. e. significantly higher than in the healthy controls (P < 0.0001). In 81.3 % of the patients with fV:Q506 DVT in the leg-pelvic vein region was found as the first manifestation, thrombosis in an atypical site in 14.4 % and isolated PE in 4.3 %. The first manifestation had occurred spontaneously in 36 % of patients with the fV:Q506 mutant (44 females, 75 males), in 53.1 % of homozygotes and in 33.5 % of heterozygotic carriers of the mutation. Conclusion: The fV Leiden mutation due to APC resistance is the most common cause of venous thrombosis and apparently one of the most common inherited diseases.
- 1 June 1999
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 124 (25/26) , 783-787
APC-Resistenz und venöse Thrombophilie: Molekulargenetische Prävalenzstudie in der deutschen Bevölkerung
Grundproblematik und Fragestellung: Zu den bedeutendsten hereditären Gerinnungsdefekten, die mit einem gesteigerten venösen Thromboserisiko einhergehen, zählt die durch die Faktor-V-R506Q-Mutation (FV-Leiden-Mutation) bedingte Resistenz gegenüber aktiviertem Protein C (APC). Da bisher für die deutsche Bevölkerung kaum Daten zur genanalytisch validierten APC-Resistenz zur Verfügung stehen, bestand das Ziel der vorliegenden Untersuchung darin, in einer großen Untersuchungsgruppe deutscher Patienten mit juvenilen venösen Thromboembolien (VTE) und einer Kontrollgruppe gesunder Personen die Prävalenz der FV-Leiden-Mutation zu ermitteln. Patienten und Methodik: Insgesamt wurden konsekutiv 1200 Patienten (689 Frauen, 511 Männer) aus verschiedenen Regionen Deutschlands untersucht, die im Alter von ≤ 45 Lebensjahren an einer durch bildgebende Verfahren gesicherten primären tiefen Venenthrombose (TVT) und (oder) Lungenembolie (LE) erkrankt waren. Die Kontrollgruppe bestand aus 740 gesunden Probanden (332 Frauen, 408 Männer; medianes Alter 33 Jahre), bei denen sich in der Eigen- und Familienanamnese keine Hinweise für thromboembolische Ereignisse fanden. Die Analyse des FV-1691-Genotypes erfolgte mittels Mnll-Restriktionsanalyse von mit der Polymerase-Ketten-Reaktion amplifizierten genomischen FV-DNA-Fragmenten. Ergebnisse: In der Kontrollgruppe ergab sich eine Prävalenz von 7,5 % für die heterozygote FV:Q506-Mutante (25 Frauen, 30 Männer). Bei den untersuchten Patienten lag die FV R506Q-Mutation bei 27,2 % vor (23,1 % heterozygot [165 Frauen, 112 Männer]; 4,1 % homozygot [33 Frauen, 16 Männer]) und war somit signifikant häufiger als bei den gesunden Kontrollpersonen (P < 0,0001). Bei 81,3 % der FV:Q506-Patienten fand sich zum Zeitpunkt der Erstmanifestation eine TVT im Bein-Beckenvenenbereich, bei 14,4 % eine Thrombose in atypischer Lokalisation und bei 4,3 % eine isolierte Lungenembolie. Bei 36,5 % aller FV:Q506-Patienten (44 Frauen, 75 Männer) bzw. 53,1 % der homozygoten und 33,5 % der heterozygoten Mutationsträger trat das Erstereignis spontan auf. Folgerung: Die durch die FV-Leiden-Mutation bedingte APC-Resistenz ist die häufigste bekannte Ursache für venöse Thrombosen und scheint eine der häufigsten Erberkrankungen überhaupt zu sein, die sich auch in der deutschen Bevölkerung in einem hohen Prozentsatz nachweisen läßt. Die funktionelle und (oder) genotypische Untersuchung auf das Vorliegen einer APC-Resistenz sollte somit im Thrombophiliescreening stets berücksichtigt werden. Background and objective: Resistance against activated protein C (APC), caused by factor V R506Q mutation (factor V Leiden mutation), is among the most important hereditary clotting defects that are associated with an increased risk of venous thrombosis. As there are hardly any data for Germany regarding APC resistance that have been validated by genetic analysis, this study was undertaken to determine the prevalence of factor V Leiden (fVL) mutations in a sizeable group of patients in Germany with venous thromboembolism (VTE) and a control group of healthy persons. Patients and methods: 1200 consecutive patients (689 females, 511 males) from various regions of Germany were examined who, at an age between 0.1 and 45 years, had developed primary deep vein thrombosis (DVT) and/or pulmonary embolism (PE), as confirmed by imaging tests. The control group consisted of 740 healthy persons (332 females and 408 males; median age 33 years) for whom there was no evidence in their personal of family history of TE. Analysis of the fV-1691 genotype was by Mnll-restriction analysis of genomic fV DNA fragments, amplified by polymerase chain reaction. Results: The prevalence in the control group was 7.5 % the for heterozygotic fV: Q506 mutant (25 females, 30 males). For the patients the prevalence of the fV R506Q mutation was 27.2 % (32.1 % heterozygotes [165 females, 112 males]; 4.1 % homozygotes [33 females, 16 males], i. e. significantly higher than in the healthy controls (P < 0.0001). In 81.3 % of the patients with fV:Q506 DVT in the leg-pelvic vein region was found as the first manifestation, thrombosis in an atypical site in 14.4 % and isolated PE in 4.3 %. The first manifestation had occurred spontaneously in 36 % of patients with the fV:Q506 mutant (44 females, 75 males), in 53.1 % of homozygotes and in 33.5 % of heterozygotic carriers of the mutation. Conclusion: The fV Leiden mutation due to APC resistance is the most common cause of venous thrombosis and apparently one of the most common inherited diseases.
- 1 March 1999
- Vol. 93 (5) , 1595-9
Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
The reported incidence of thromboembolism in children with acute lymphoblastic leukemia (ALL) treated with L-asparaginase, vincristine, and prednisone varies from 2.4% to 11.5%. The present study was designed to prospectively evaluate the role of the TT677 methylenetetrahydrofolate reductase (MTHFR) genotype, the prothrombin G20210A mutation, the factor V G1691A mutation, deficiencies of protein C, protein S, antithrombin, and increased lipoprotein (a) concentrations in leukemic children treated according to the ALL-Berlin-Frankfurt-Muenster (BFM) 90/95 study protocols with respect to the onset of vascular events. Three hundred and one consecutive leukemic children were enrolled in this study. Fifty-five of these 301 subjects investigated had one established single prothrombotic risk factor: 20 children showed the TT677 MTHFR genotype; 5 showed the heterozygous prothrombin G20210A variant; 11 were carriers of the factor V G1691A mutation (heterozygous, n = 10; homozygous, n = 1); 4 showed familial protein C, 4 protein S, and 2 antithrombin type I deficiency; 9 patients were suffering from familially increased lipoprotein (a) [Lp(a)] concentrations (>30 mg/dL). In addition, combined prothrombotic defects were found in a further 10 patients: the FV mutation was combined with the prothrombin G20210A variant (n = 1), increased Lp(a) (n = 3), protein C deficiency (n = 1), and homozygosity for the C677T MTHFR gene mutation (n = 1). Lp(a) was combined with protein C deficiency (n = 2) and the MTHFR TT 677 genotype (n = 2). Two hundred eighty-nine of the 301 patients were available for thrombosis-free survival analysis. In 32 (11%) of these 289 patients venous thromboembolism occurred. The overall thrombosis-free survival in patients with at least one prothrombotic defect was significantly reduced compared with patients without a prothrombotic defect within the hemostatic system (P <.0001). In addition, a clear-cut positive correlation (P <.0001) was found between thrombosis and the use of central lines. However, because the prothrombotic defects diagnosed in the total childhood population studied were all found within the prevalences reported for healthy Caucasian individuals, the interaction between prothrombotic risk factors, ALL treatment, and further environmental factors is likely to cause thrombotic manifestations.
- 1 March 1999
- Vol. 93 (5) , 1595-9
Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
The reported incidence of thromboembolism in children with acute lymphoblastic leukemia (ALL) treated with L-asparaginase, vincristine, and prednisone varies from 2.4% to 11.5%. The present study was designed to prospectively evaluate the role of the TT677 methylenetetrahydrofolate reductase (MTHFR) genotype, the prothrombin G20210A mutation, the factor V G1691A mutation, deficiencies of protein C, protein S, antithrombin, and increased lipoprotein (a) concentrations in leukemic children treated according to the ALL-Berlin-Frankfurt-Muenster (BFM) 90/95 study protocols with respect to the onset of vascular events. Three hundred and one consecutive leukemic children were enrolled in this study. Fifty-five of these 301 subjects investigated had one established single prothrombotic risk factor: 20 children showed the TT677 MTHFR genotype; 5 showed the heterozygous prothrombin G20210A variant; 11 were carriers of the factor V G1691A mutation (heterozygous, n = 10; homozygous, n = 1); 4 showed familial protein C, 4 protein S, and 2 antithrombin type I deficiency; 9 patients were suffering from familially increased lipoprotein (a) [Lp(a)] concentrations (>30 mg/dL). In addition, combined prothrombotic defects were found in a further 10 patients: the FV mutation was combined with the prothrombin G20210A variant (n = 1), increased Lp(a) (n = 3), protein C deficiency (n = 1), and homozygosity for the C677T MTHFR gene mutation (n = 1). Lp(a) was combined with protein C deficiency (n = 2) and the MTHFR TT 677 genotype (n = 2). Two hundred eighty-nine of the 301 patients were available for thrombosis-free survival analysis. In 32 (11%) of these 289 patients venous thromboembolism occurred. The overall thrombosis-free survival in patients with at least one prothrombotic defect was significantly reduced compared with patients without a prothrombotic defect within the hemostatic system (P <.0001). In addition, a clear-cut positive correlation (P <.0001) was found between thrombosis and the use of central lines. However, because the prothrombotic defects diagnosed in the total childhood population studied were all found within the prevalences reported for healthy Caucasian individuals, the interaction between prothrombotic risk factors, ALL treatment, and further environmental factors is likely to cause thrombotic manifestations.
- 1 January 1997
- Vol. 21 (5) , 452-9
Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Proteolytic destruction of basement membrane and tumor surrounding is a prerequisite of invasion and metastasis. In 587 frozen samples of malignant and nonmalignant tissue of breast, uterus, vulva, and ovary, levels of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) were examined with enzyme-linked immunosorbent assay (ELISA) and cathepsin D (cath D) with radioimmunoassay. UPA, PAI-1 and cath D were raised in malignant tissue with significantly higher levels in breast cancer (uPA, PAI-1) and ovarian cancer (cath D). TPA levels were lower in malignant tissue. In 393 primary breast cancer samples, uPA, PAI-1, and cath D were not related to other prognostic factors, whereas tPA levels were significantly raised in prognostic more favorable carcinomas. Over a follow-up period up to 46 months (median 30 months) the log-rank test showed in the whole group of breast cancer patients a significantly higher rate of relapse (p < 0.05) and death (p < 0.001) with tPA levels < 2.5 ng/mg. PAI-1 levels > 3 ng/mg were associated with shorter overall (p < 0.02; p = 0.01), disease-free (p < 0.008; p < 0.01), and metastasis-free (p < 0.04; p = 0.005) survival in all patients and in the node-negative subgroup, respectively. Higher uPA and cath D levels were not associated with rate of relapse or death over this follow-up period. The prognostic value of tumor-associated proteases could be of interest also in ovarian and cervical cancer.
- 1 January 1997
- Vol. 21 (5) , 452-9
Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Proteolytic destruction of basement membrane and tumor surrounding is a prerequisite of invasion and metastasis. In 587 frozen samples of malignant and nonmalignant tissue of breast, uterus, vulva, and ovary, levels of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) were examined with enzyme-linked immunosorbent assay (ELISA) and cathepsin D (cath D) with radioimmunoassay. UPA, PAI-1 and cath D were raised in malignant tissue with significantly higher levels in breast cancer (uPA, PAI-1) and ovarian cancer (cath D). TPA levels were lower in malignant tissue. In 393 primary breast cancer samples, uPA, PAI-1, and cath D were not related to other prognostic factors, whereas tPA levels were significantly raised in prognostic more favorable carcinomas. Over a follow-up period up to 46 months (median 30 months) the log-rank test showed in the whole group of breast cancer patients a significantly higher rate of relapse (p < 0.05) and death (p < 0.001) with tPA levels < 2.5 ng/mg. PAI-1 levels > 3 ng/mg were associated with shorter overall (p < 0.02; p = 0.01), disease-free (p < 0.008; p < 0.01), and metastasis-free (p < 0.04; p = 0.005) survival in all patients and in the node-negative subgroup, respectively. Higher uPA and cath D levels were not associated with rate of relapse or death over this follow-up period. The prognostic value of tumor-associated proteases could be of interest also in ovarian and cervical cancer.
- 1 March 1994
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 4 (3) , 717-721
PROTEASES ASSOCIATED WITH GYNECOLOGICAL TUMORS
Proteases are involved in the invasion and metastasis of tumours by destruction of the basal membrane and connective tissue. As levels in malignant tissue have both prognostic and therapeutic implications, we examined 318 frozen samples from malignant tumours and comparable non-malignant tissue looking for urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels with ELISA, as well as cathepsin D with RIA. Oestrogen receptor (ER) levels, progesterone receptor (PrgR) levels and epidermal growth factor receptors (EGFR) were measured by biochemical methods at the same time. Significantly raised levels of uPA, PAI-1 and cathepsin D were found in malignant tissue, with PAI-1 particularly high in carcinoma of the cervix. Significantly raised tPA levels were found in breast cancer tissue with a more favourable clinical prognosis, with a positive correlation between tPA and ER. No correlation could be shown between uPA, PAI-1 and cathepsin D with other prognostic factors for breast cancer. It could be that routine, uncomplicated estimation of tumour-associated proteases such as uPA, tPA, PAI-1 and cathepsin D will provide an independent prognostic marker for therapeutic decisions with regard to gynaecological tumours and breast cancer.
- 1 March 1994
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 4 (3) , 717-721
PROTEASES ASSOCIATED WITH GYNECOLOGICAL TUMORS
Proteases are involved in the invasion and metastasis of tumours by destruction of the basal membrane and connective tissue. As levels in malignant tissue have both prognostic and therapeutic implications, we examined 318 frozen samples from malignant tumours and comparable non-malignant tissue looking for urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels with ELISA, as well as cathepsin D with RIA. Oestrogen receptor (ER) levels, progesterone receptor (PrgR) levels and epidermal growth factor receptors (EGFR) were measured by biochemical methods at the same time. Significantly raised levels of uPA, PAI-1 and cathepsin D were found in malignant tissue, with PAI-1 particularly high in carcinoma of the cervix. Significantly raised tPA levels were found in breast cancer tissue with a more favourable clinical prognosis, with a positive correlation between tPA and ER. No correlation could be shown between uPA, PAI-1 and cathepsin D with other prognostic factors for breast cancer. It could be that routine, uncomplicated estimation of tumour-associated proteases such as uPA, tPA, PAI-1 and cathepsin D will provide an independent prognostic marker for therapeutic decisions with regard to gynaecological tumours and breast cancer.
- 1 January 1994
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 72 (05) , 784-785
Variables that Might Affect the Outcome of Immune Tolerance Therapy in Haemophiliacs with Factor VIII Inhibitors
- 1 January 1994
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 72 (05) , 784-785
Variables that Might Affect the Outcome of Immune Tolerance Therapy in Haemophiliacs with Factor VIII Inhibitors
- 1 November 1991
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 203 (06) , 424-428
Hämostaseologische Veränderungen bei ,,idiopathischen" venösen Thrombosen im Kindes- und Jugendalter
The prevalence of inherited thrombotic syndrome in the general population appears to be higher than that of inherited bleeding disorders. The most important candidates for screening are patients with unexplained venous thromboembolism at ages of less than 40 years: In 18 children and adolescents suffering from "idiopathic" vein thrombosis laboratory screening has been performed: PT, PTT, TT, platelet count, spontaneous platelet aggregation, von Willebrand factor, fibrinogen, plasminogen, antithrombin III, protein C, C1-inactivator, alpha-1-antitrypsin, alpha-1-antichymotrypsin, alpha-2-antiplasmin and alpha-2-macroglobulin. Compared to an age matched healthy control group in children with idiopathic vein thrombosis we could demonstrate in vitro platelet activation with significant enhanced platelet aggregation and elevated levels of von Willebrand factor in the onset of the disease. Antithrombin III, protein C, alpha-2-antiplasmin and alpha-2-macroglobulin were significantly decreased. These changes turned to be normal in the following 6 to 9 months. PT, PTT, TT, platelet count, plasminogen, alpha-1-antitrypsin, alpha-1-antichymotrypsin and c1-inactivator showed no alterations compared to the control. Platelet activation and alteration of platelet function in vivo and in vitro is established to initiate thrombosis. The von Willebrand's VIII molecule is involved in this step. The decreased inhibitors of the hemostatic system antithrombin III and protein C in the onset period of thrombotic diseases are discussed to be an increased turnover, whereas the decreased levels of alpha-2-antiplasmin and alpha-2-macroglobulin might be a counter-regulation to the thrombotic event, showing an "activated" fibrinolytic system.
- 1 November 1991
- Published by Georg Thieme Verlag KG in Klinische Padiatrie
- Vol. 203 (06) , 424-428
Hämostaseologische Veränderungen bei ,,idiopathischen" venösen Thrombosen im Kindes- und Jugendalter
The prevalence of inherited thrombotic syndrome in the general population appears to be higher than that of inherited bleeding disorders. The most important candidates for screening are patients with unexplained venous thromboembolism at ages of less than 40 years: In 18 children and adolescents suffering from "idiopathic" vein thrombosis laboratory screening has been performed: PT, PTT, TT, platelet count, spontaneous platelet aggregation, von Willebrand factor, fibrinogen, plasminogen, antithrombin III, protein C, C1-inactivator, alpha-1-antitrypsin, alpha-1-antichymotrypsin, alpha-2-antiplasmin and alpha-2-macroglobulin. Compared to an age matched healthy control group in children with idiopathic vein thrombosis we could demonstrate in vitro platelet activation with significant enhanced platelet aggregation and elevated levels of von Willebrand factor in the onset of the disease. Antithrombin III, protein C, alpha-2-antiplasmin and alpha-2-macroglobulin were significantly decreased. These changes turned to be normal in the following 6 to 9 months. PT, PTT, TT, platelet count, plasminogen, alpha-1-antitrypsin, alpha-1-antichymotrypsin and c1-inactivator showed no alterations compared to the control. Platelet activation and alteration of platelet function in vivo and in vitro is established to initiate thrombosis. The von Willebrand's VIII molecule is involved in this step. The decreased inhibitors of the hemostatic system antithrombin III and protein C in the onset period of thrombotic diseases are discussed to be an increased turnover, whereas the decreased levels of alpha-2-antiplasmin and alpha-2-macroglobulin might be a counter-regulation to the thrombotic event, showing an "activated" fibrinolytic system.